Brief: Mediwound Announces U.S. FDA Acceptance Of Biologics License Application For Nexobrid For Treatment Of Severe Thermal Burns

Vericel

03/08/2022 13:09

Aug 3 (Reuters) - Mediwound Ltd  MDWD.O :
    * MEDIWOUND ANNOUNCES U.S. FDA ACCEPTANCE OF BIOLOGICS
LICENSE
APPLICATION FOR NEXOBRID FOR THE TREATMENT OF SEVERE THERMAL
BURNS
    * MEDIWOUND LTD - FDA ASSIGNED A PRESCRIPTION DRUG USER FEE
ACT
(PDUFA) TARGET DATE OF JANUARY 1, 2023

Source text for Eikon:  ID:nGNXbvr1Cb 
Further company coverage:  MDWD.O 

 ((Reuters.Briefs@thomsonreuters.com;))